Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
KYMR
KYMR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KYMR News
Kymera Therapeutics Presents KT-621 Phase 1 Study Results at JDA
Jun 12 2026
Newsfilter
Novartis Expands Deal with Orionis for Molecular Glue Drugs
Jun 11 2026
seekingalpha
Kymera Therapeutics Secures $20 Million Milestone Payment from Sanofi
Jun 09 2026
Yahoo Finance
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
May 17 2026
Yahoo Finance
Purcell & Lefkowitz Investigates Kymera Therapeutics for Fiduciary Breaches
May 12 2026
PRnewswire
Key Wall Street Rating Changes Overview
May 06 2026
CNBC
Kymera Therapeutics Q1 2026 Earnings Call Insights
Apr 30 2026
seekingalpha
Kymera Therapeutics Q1 Earnings Announcement Scheduled
Apr 29 2026
seekingalpha
Kymera's KT-621 Receives FDA Fast Track Designation
Apr 13 2026
NASDAQ.COM
Kymera Therapeutics' KT-621 Receives FDA Fast Track Designation
Apr 13 2026
Newsfilter
KYMERA THERAPEUTICS INC - GILEAD TO PROGRESS KT-200 INTO STUDIES PREPARING FOR IND FILING IN 2027
Apr 09 2026
moomoo
KYMERA THERAPEUTICS REVEALS GILEAD SCIENCES HAS EXERCISED OPTION TO LICENSE KT-200, AN ORAL CDK2 MOLECULAR GLUE DEGRADER CANDIDATE
Apr 09 2026
moomoo
Nextech Reduces Stake in Kymera Therapeutics: Analysis
Mar 19 2026
NASDAQ.COM
Nextech Reduces Stake in Kymera Therapeutics
Mar 19 2026
Fool
Analysis of KYMR Options Trading Dynamics
Mar 03 2026
NASDAQ.COM
Kymera Therapeutics (KYMR.US) Insider Plans to Sell $18.27 Million in Common Stock via Form 144
Mar 02 2026
moomoo
Show More News
